Noninvasive Prenatal Diagnostics: Recent Developments Using Circulating Fetal Nucleated Cells.
Chen Pin-JungTeng Pai-ChiYazhen ZhuYu Jen JanMatthew SmalleyYalda AfsharChen Li-ChingMargareta D PisarskaTseng Hsian-RongPublished in: Current obstetrics and gynecology reports (2019)
Invasive prenatal diagnostic procedures, amniocentesis and chorionic villus sampling, are the gold standard for the diagnosis of fetal chromosomal abnormalities and genetic disorders. Meanwhile, noninvasive techniques of analyzing circulating cell-free fetal DNA (cffDNA) have been limited to screening tools and are highly fragmented and confounded by maternal DNA. By detecting circulating fetal nucleated cells (CFNCs) we are able to noninvasively confirm fetal chromosomal abnormalities, truly realizing the concept of "noninvasive prenatal diagnostics". The primary technical challenge is the enrichment of the low abundance of CFNCs in maternal peripheral blood. For any cell-based NIPD method, both fetal whole genome profiling and confirmation of the feto-parental relationship are essential. This has been successfully performed using enriched and isolated cTBs, making cTB a better candidate for NIPD. cTB enumeration also correlates with abnormal fetal or placental development. On the other hand, downstream analysis of fNRBCs remains limited to examining fetal sex and aneuploidies. Furthermore, trophoblast-based NIPD via an endocervical sample is also promising because of reduced dilution from hematologic cells.
Keyphrases
- cell free
- induced apoptosis
- pregnant women
- peripheral blood
- circulating tumor
- stem cells
- single molecule
- oxidative stress
- genome wide
- copy number
- signaling pathway
- gene expression
- mesenchymal stem cells
- cell therapy
- physical activity
- wastewater treatment
- liquid chromatography tandem mass spectrometry
- ms ms
- bone marrow
- preterm birth
- circulating tumor cells
- weight loss
- gas chromatography